by Truveta Research | Dec 14, 2024 | Research, Research Insights
First-time amphetamine/dextroamphetamine prescription rates remained stable overall, but increased significantly for people 30-44, 45-64, and 65+ years of age. The percentage of prescriptions filled within 5 days of being written reached their lowest values in March...
by Truveta staff | Nov 7, 2024 | Data
GLP-1 medications are revolutionizing the way we treat type 2 diabetes and obesity. First discovered forty years ago, GLP-1 receptor agonists were initially approved for type 2 diabetes in 2005, with the first weight-loss-specific approval following in 2014. Flash...
by Truveta staff | Jun 17, 2024 | Data, News, Technology
Truveta now offers regulatory and audit capabilities to support our customers for real-world evidence (RWE) submissions to the Food and Drug Administration (FDA) and other global regulatory authority decisions. These regulatory grade capabilities advance Truveta’s...
by Truveta staff | Mar 11, 2024 | Research
Each year, approximately 900,000 patients in the US are affected by a pulmonary embolism (PE), a blood clot causing a blockage in one or more pulmonary arteries in the lungs. PE is a leading cause of in-hospital death in the US, and acute PE – a sudden blockage...
